SS-31 (Elamipretide) vs Thymosin Beta-4
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
SS-31 (Elamipretide)Recovery & RepairAnti-Aging & Longevity
Thymosin Beta-4- Summary
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Thymosin Beta-4 is an endogenous 43-amino acid peptide that is the primary intracellular actin sequestering peptide. It promotes tissue repair, reduces inflammation, regenerates hair follicles, and protects cardiac tissue. Closely related to TB-500 (the active fragment), it is used for systemic tissue recovery and anti-aging.
- Half-Life
- ~2–5 hours
- Not well characterized; likely similar to TB-500 (~1–2 hours)
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 5–10 mg
- 5–10 mg
- Frequency
- Daily to several times per week
- 2x per week (loading), then 1x per week (maintenance)
- Key Benefits
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Systemic tissue repair and regeneration
- Promotes cardiac recovery after myocardial infarction
- Hair follicle regeneration and anti-hair-loss
- Anti-inflammatory (systemic)
- Wound healing acceleration
- Neuroprotection after brain injury
- Protects against ischemia-reperfusion injury
- Anti-aging at cellular level
- Synergizes powerfully with BPC-157
- Side Effects
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Generally very well tolerated
- Injection site reactions
- Mild fatigue at initiation (repair signaling)
- Rare: mild inflammatory response
- +1 more
- Stacks With
- —
- —